Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review
about
Disclosing conflicts of interest in patient decision aidsInteraction and medical inducement between pharmaceutical representatives and physicians: a meta-synthesisKnowledge, beliefs and attitudes of physicians in low and middle-income countries regarding interacting with pharmaceutical companies: a systematic reviewDoctors and drug companies: still cozy after all these yearsAdherence of pharmaceutical advertisements in medical journals to FDA guidelines and content for safe prescribingComplaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004-2012: a quantitative and qualitative study of pharmaceutical industry self-regulationContact between doctors and the pharmaceutical industry, their perceptions, and the effects on prescribing habitsPrescription Drug Promotion from 2001-2014: Data from the U.S. Food and Drug AdministrationPhysician Payments from Industry Are Associated with Greater Medicare Part D Prescribing CostsTurkish Final Year Medical Students' Exposure to and Attitudes Concerning Drug Company Interactions: A Perspective from a Minimally Regulated Environment for Medical StudentsGlobal health philanthropy and institutional relationships: how should conflicts of interest be addressed?Association between physicians' interaction with pharmaceutical companies and their clinical practices: A systematic review and meta-analysisPharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States.Finding type 2 diabetes causal single nucleotide polymorphism combinations and functional modules from genome-wide association data.Effects of the expansion of doctors' offices adjacent to private pharmacies in Mexico: secondary data analysis of a national survey.The rise of digital direct-to-consumer advertising?: Comparison of direct-to-consumer advertising expenditure trends from publicly available data sources and global policy implications.Awareness and attitudes of the Lebanese population with regard to physician-pharmaceutical company interaction: a survey study.Exposure to the drug company marketing in Greece: Interactions and attitudes in a non-regulated environment for medical students.What keeps family physicians busy in Portugal? A multicentre observational study of work other than direct patient contactsGPs' opinions of public and industrial information regarding drugs: a cross-sectional study.Chronological changes in Japanese physicians' attitude and behavior concerning relationships with pharmaceutical representatives: a qualitative study.Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohortAssociation of medical students' reports of interactions with the pharmaceutical and medical device industries and medical school policies and characteristics: a cross-sectional study.Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model.Misleading advertising for antidepressants in Sweden: a failure of pharmaceutical industry self-regulation.Application of propensity scores to estimate the association between government subsidy and injection use in primary health care institutions in ChinaToo few, too weak: conflict of interest policies at Canadian medical schoolsAntipsychotic prescribing: do conflict of interest policies make a difference?Sources of drug information and their influence on the prescribing behaviour of doctors in a teaching hospital in Ibadan, Nigeria.Design and evaluation of a software for the objective and easy-to-read presentation of new drug properties to physiciansEvaluating medication-related quality of care in residential aged care: a systematic review.Between government policy, clinical autonomy, and market demands: a qualitative study of the impact of the Prescribing Analysis System on behavior of physicians in South Korea.Perceptions and Attitudes of Egyptian Health Professionals and Policy-Makers towards Pharmaceutical Sales Representatives and Other Promotional ActivitiesValidity of tools used for surveying physicians about their interactions with pharmaceutical company: a systematic reviewEffect of Direct-to-Consumer Advertising on Asthma Medication Sales and Healthcare Use.Of money and trust in medical care redux.The updated AMSA scorecard of conflict-of-interest policies: a survey of U.S. medical schools.Knowledge, Beliefs and Attitudes of Patients and the General Public towards the Interactions of Physicians with the Pharmaceutical and the Device Industry: A Systematic Review.Knowledge transfer: what drug information would specialist doctors need to support their clinical practice? Results of a survey and of three focus groups in Italy.Models for financing the regulation of pharmaceutical promotion.
P2860
Q26863432-97D951E5-D4DD-4FFC-8CFC-380ED3BAE34EQ28071334-AC683393-9A41-41DF-9E60-6F4012B42E6DQ28078675-A7ED9EDF-04BA-4F3F-9E61-B981190EC4B1Q28475991-A77C2F79-946C-49FA-9E7E-E6C58001F723Q28476593-93AE36B0-123C-49FA-A2D1-0A36EA64BF81Q28543449-14A0329C-8AB9-48C0-8E5A-CB4298F4CE78Q28543878-57F8C33C-B999-461B-BC82-C45510209724Q28551840-8679B9D0-8E08-49D0-BF0D-E8C91F78415FQ28552099-D9E60894-538B-4567-A165-BD2717FA126CQ28555046-D6F6AF8F-3528-4996-800A-98EA93ADCC59Q28741208-2E1CE6F2-9C91-4BCC-9E4F-0C13EF15B742Q29994595-E7B32261-B89B-408F-8835-A45D10938F16Q30547338-F3EAAE2C-1AE2-414D-89B9-C95485C38125Q30613341-68B49620-A19A-4D97-A8CF-86FB7311126BQ30825750-FC861998-C804-4BC3-862B-D9EFC13C2282Q30974238-649B7C03-F4C7-4531-824F-934E3CDC6D08Q33552695-EEFA0F18-FD85-4533-A30C-765DA9ED42E9Q33753326-0A07C3B9-1FFD-4302-A3BE-0C09DFB1ECFCQ33795605-3B0565CD-23CA-41D2-A26E-67731E584745Q34002827-C541D52A-D93C-4C3E-BF32-E477AD42D74DQ34215520-2D1C5238-B357-415C-B8AE-177BC8E383C4Q34264302-2C612789-AFA7-4077-AD31-34CA6A0162E7Q34337342-CFF8CF63-2114-4747-9CA6-1733A2101ADAQ34372885-8C75FB7E-AB8C-4475-95F3-47B1D703B0FBQ34708396-75E905D4-9652-4D1F-84C6-5D9598663FBEQ34729103-27C2F2F4-C558-4500-A57D-D82216DD198AQ34827912-31D3B5CC-FDF7-4C38-944F-F649EFE3DD14Q35180226-BBF94042-25D4-4033-9FCF-6819DB24F2E3Q35548261-12B4672B-D1C6-4ECD-8D56-E6B09C55703BQ35646560-04548A41-1A7F-487A-8E88-01E894E8106AQ35685992-8EFFFFAE-095B-44C6-9234-B1C8866FADD2Q35782793-066526A6-9C9F-4043-834D-11A0DC4ABF40Q35810078-44814853-08E6-4FA2-9A8E-A97F69C94A67Q35852800-46FB175C-3AE7-426D-9456-C01B861FFBB6Q35879680-2B60C2F9-417C-4F58-B9BD-8F84BAC078A6Q35964324-717AFEB5-9DA7-4EF2-8FD5-1F740A95F542Q36103107-F4EC096A-E01C-46F1-80D1-22BCBFA55A3BQ36111491-AC5FCD10-1629-492E-B62D-FCF673636791Q36119076-5F67D2A4-1E19-41BE-B31C-5D55DC353B83Q36138721-98570CD9-BF41-4B2E-AF99-13BE02B1B460
P2860
Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Information from pharmaceutica ...... escribing: a systematic review
@ast
Information from pharmaceutica ...... escribing: a systematic review
@en
Information from pharmaceutica ...... escribing: a systematic review
@nl
type
label
Information from pharmaceutica ...... escribing: a systematic review
@ast
Information from pharmaceutica ...... escribing: a systematic review
@en
Information from pharmaceutica ...... escribing: a systematic review
@nl
prefLabel
Information from pharmaceutica ...... escribing: a systematic review
@ast
Information from pharmaceutica ...... escribing: a systematic review
@en
Information from pharmaceutica ...... escribing: a systematic review
@nl
P2093
P2860
P31
P50
P3181
P1433
P1476
Information from pharmaceutica ...... escribing: a systematic review
@en
P2093
Brett D Montgomery
Joel Lexchin
Noordin Othman
Peter R Mansfield
P2860
P304
P3181
P356
10.1371/JOURNAL.PMED.1000352
P407
P577
2010-10-19T00:00:00Z